Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?

AIDS

Volumn 26, Issue 9, 2012, Pages 1167-1169

  Kuhn, Louise ^a,b   Bulterys, Marc ^c,d  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Columbia University ^*  (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

bone; growth; HIV; perinatal; pregnancy; tenofovir

Indexed keywords

TENOFOVIR;

DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; OUTCOME ASSESSMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRENATAL GROWTH; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

ADENINE; ANTI-HIV AGENTS; BODY SIZE; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84861494412     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283536b5e     Document Type: Note

References (31)

1. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breastfeeding in Botswana. N Engl J Med 2010; 362:2282-2294.
2. Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
3. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378:282-284.
4. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, et al. Universal antiretroviral therapy for pregnant and breastfeeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009; 49:1936-1945.
5. Bulterys M, Wilfert C. HAART during pregnancy and during breastfeeding among HIV-infected women in the developing world: has the time come? AIDS 2009; 23:2473-2477.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011. pp. 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf2011. [Accessed 31 January 2012]
7. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.NEngl J Med 2006; 354:251-260.
8. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
9. Baeten J, Celum C; the Partners in PrEP Study. Antiretroviral preexposure prophylaxis for HIV-1 prevention among heterosexual African men and women. In: Proceedings of the 6th International AIDS Society Conference; 17-20 July 2011; Rome, Italy (abstract #MOAX0106).
10. Thigpen M, Kebaabetswe P, Smith D, Segolodi T, Soud F, Chillag K, et al. Daily oral antiretroviral use for prevention of HIV infection in heterosexually active young adults in Botswana: Results from the TDF2 study. In: Proceedings of the 6th International AIDS Society Conference; 17-20 July 2011; Rome, Italy (abstract #WELBC01).
11. Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011; 58:207-210.
12. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
13. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
14. Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States-14 September 2011. Available at http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL. pdf. 2011. (Accessed 31 January 2012)
15. Cotter AG, Powderly WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Pract Res Clin Endocrinol Metab 2011; 25:501-515.
16. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-220.
17. Van Rompay KK, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004; 48:1469-1487.
18. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-3160.
19. Siberry GK, Williams PL, Mendez H, Seage GR, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-1159.
20. Lanham SA, Bertram C, Cooper C, Oreffo RO. Animal models of maternal nutrition and altered offspring bone structure-bone development across the lifecourse. Eur Cell Mater 2011; 22:321-332.
21. Vigano A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIVuninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-1266.
22. Mora S, Giacomet V, Vigano A, Cafarelli L, Stucchi S, Pivetti V, et al. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone 2012; 50:255-258.
23. Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Long-term mitochondrial toxicity in HIVuninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183.
24. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25:2301-2304.
25. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 2009; 10:397-406.
26. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
27. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138-145.
28. Chi BH, Sinkala M, Mbewe F, Cantrell RA, Kruse G, Chintu N, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to nonnucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-1705.
29. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 2007; 4:135-140.
30. Spector SA. Vitamin D earns more than a passing grade. J Infect Dis 2009; 200:1015-1017.
31. Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS 2012; 26:253-262.